CAS: 1093-58-9; (8R,9S,10R,13S,14S,17S)-4-Chloro-17-Hydroxy-10,13-Dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-Dodecahydrocyclopenta[a]Phenanthren-3-One

上下游产品

CAS号855-19-6 醋酸氯睾酮 | CAS号2189-83-5 17|A-Hydroxy-5-... | CAS号58-22-0 睾酮

📜17β-Hydroxy-4β,5-Epoxy-5β-Androstan-3-One置于盐酸体系中,化学反应生成氯司替勃
参考文献:Steroids. Lxxxii.1 Synthesis Of 4-Halo Hormone Analogs
标题:Steroids. Lxxxii.1 Synthesis Of 4-Halo Hormone Analogs
摘要:
Doi:10.1021/jo01118A028

专利信息

专利号:US-2014274978-A1
优先权日:2013-03-15
标题 :Phytosterol spirostane and spirostene derivatives having a wide variety of utilities in humans and other animals
发明人：FASCIOLA ANDRE ARMEL
权利人:FASCIOLA ANDRE ARMEL
摘要:The present invention utilizes phytosterol, phytoecdysteroid, sapogenin, triterpene, terpene, spirostane, spirostene and androstene derivative compounds to provide a wide variety of utilities to humans and other animals. The compounds and methods provide numerous and wide-ranging benefits including biochemical and constructive metabolic benefits including increases in protein synthesis and synthesis efficiency, ergogenic, adaptogenic, cosmetic and medicinal skin agents and veterinary utilities. The compounds provide agents that increase physical endurance and work output, act as a general tonic for increasing health and vigor, increase sleep time and sleep efficiency and act as rejuvenating agents to reverse the effects of fatigue and stress. Novel utilities for pet, farm, zoo and companion animals are also provided.

专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.